|
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate c |
100.00% |
|
75 year old man, Prostate Cancer with bone and liver metastasis |
100.00% |
|
Intermittent androgen deprivation therapy: redefining the standard of care? |
100.00% |
|
3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. |
100.00% |
|
Bio-Immune therapy according to Professor Thomas Tallberg, a cure for Melanoma? |
97.50% |
|
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ...... |
95.00% |
|
20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and |
90.00% |
|
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell |
90.00% |
|
Clinical Investigations on Ukrain |
90.00% |
|
A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. |
90.00% |
|
The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications |
90.00% |
|
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prosta |
90.00% |
|
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients ..... |
90.00% |
|
Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention |
90.00% |
|
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. |
90.00% |
|
GcMAF-The cancer revolution from Japan |
87.50% |
|
Systems biology: a therapeutic target for tumor therapy. |
86.67% |
|
Todoxin, the immune stimulant from Serbia |
86.36% |
|
82 year old man with prostate cancer |
85.00% |
|
Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer |
80.00% |
|
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refract |
80.00% |
|
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. |
80.00% |
|
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. |
80.00% |
|
Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. |
80.00% |
|
An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis. |
80.00% |
|
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. |
80.00% |
|
Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate ca |
80.00% |
|
High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomised study. |
80.00% |
|
Clinical experience of integrative cancer immunotherapy with GcMAF. |
80.00% |
|
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. |
80.00% |
|
Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. |
80.00% |
|
Melatonin as biological response modifier in cancer patients. |
80.00% |
|
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. |
80.00% |
|
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen |
80.00% |
|
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. |
80.00% |
|
Metformin in the treatment of Cancer |
77.00% |
|
Cancer Psychotherapy according to Dr. Frederick B Levenson |
76.00% |
|
Removed from Pubmed because of suspiion of scientific fraud: Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. |
75.00% |
|
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline |
70.00% |
|
Focal laser ablation of prostate cancer: definition, needs, and future |
70.00% |
|
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. |
70.00% |
|
Association between serum 25(OH)D and death from prostate cancer. |
70.00% |
|
Oncolytic virus therapy for prostate cancer. |
70.00% |
|
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. |
70.00% |
|
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-indep.. |
70.00% |
|
A phase II trial of an adenovirus/PSA vaccine for prostate cancer. |
70.00% |
|
Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. |
70.00% |
|
Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate |
60.00% |
|
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. |
60.00% |
|
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. |
60.00% |
|
Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of |
60.00% |
|
Focal therapy for prostate cancer: revolution or evolution? |
60.00% |
|
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. |
60.00% |
|
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. |
60.00% |
|
Serum calcium and the risk of prostate cancer. |
60.00% |
|
Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. |
60.00% |
|
Vitamin D and prostate cancer risk: a review of the epidemiological literature. |
60.00% |
|
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. |
50.00% |
|
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. |
50.00% |
|
Results of Ukrain monotherapy of prostate cancer |
50.00% |
|
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. |
50.00% |
|
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryother |
50.00% |
|
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. |
50.00% |
|
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. |
50.00% |
|
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities |
50.00% |
|
Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. |
|
|
Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. |
|
|
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) stud |
|
|
PSMA - Lutetium Treatment |
|
